LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Myriad Genetics Inc

Closed

SectorHealthcare

5.34 4.09

Overview

Share price change

24h

Current

Min

5.02

Max

5.34

Key metrics

By Trading Economics

Income

42M

-100K

Sales

-15M

196M

EPS

-0.03

Profit margin

-0.051

Employees

2,700

EBITDA

-12M

-14M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+71.09% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-869M

448M

Previous open

1.25

Previous close

5.34

News Sentiment

By Acuity

50%

50%

165 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Myriad Genetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jun 2025, 22:09 UTC

Earnings

Alimentation Couche-Tard 4Q Profit Falls on Lower Fuel Prices, Demand

25 Jun 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy

25 Jun 2025, 20:38 UTC

Earnings

Micron Technology 3Q Profit Soars as AI Boom Boosts Sales

25 Jun 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears Over Middle East Ease -- Market Talk

25 Jun 2025, 23:39 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Uncertainties -- Market Talk

25 Jun 2025, 23:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Xero Probably Sees Value in Melio's Syndication Network -- Market Talk

25 Jun 2025, 23:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

25 Jun 2025, 21:36 UTC

Earnings

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25 Jun 2025, 21:34 UTC

Earnings

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25 Jun 2025, 21:23 UTC

Earnings

Micron's Profit Soars as AI Boom Boosts Sales -- Update

25 Jun 2025, 21:08 UTC

Earnings

Couche-Tard 4Q Canada Same-Store Merchandise Revenues Up 3.5% >ATD.T

25 Jun 2025, 21:07 UTC

Earnings

Couche-Tard 4Q U.S. Same-Store Merchandise Revenues Down 0.4% >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Rev $16.27B >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Adj EPS 46c >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q EPS 46c >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Net $439.4M >ATD.T

25 Jun 2025, 20:49 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:32 UTC

Earnings

FedEx Earnings Topped Estimates. The Stock Is Fell. -- Barrons.com

25 Jun 2025, 20:27 UTC

Earnings

Winnebago Stock Hits a 5-Year Low. What It Means for the RV Industry. -- Barrons.com

25 Jun 2025, 20:26 UTC

Earnings

These Stocks Moved the Most Today: BP, FedEx, QuantumScape, BlackBerry, Nvidia, AeroVironment, and More -- Barrons.com

25 Jun 2025, 20:24 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:10 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:04 UTC

Earnings

Micron Technology Sees 4Q Adj EPS $2.35-Adj EPS $2.65 >MU

25 Jun 2025, 20:04 UTC

Earnings

Micron Technology Sees 4Q EPS $2.14-EPS $2.44 >MU

25 Jun 2025, 20:03 UTC

Earnings

Micron Technology Sees 4Q Rev $10.4B-$11B >MU

25 Jun 2025, 20:02 UTC

Earnings

Micron Technology: On Track to Deliver Record Rev With Solid Profitability and Free Cash Flow in FY25 >MU

25 Jun 2025, 20:02 UTC

Earnings

Micron Technology: Record Rev in Fiscal 3Q With Growth Across End Markets >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q Net $1.89B >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q Adj EPS $1.91 >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q EPS $1.68 >MU

Peer Comparison

Price change

Myriad Genetics Inc Forecast

Price Target

By TipRanks

71.09% upside

12 Months Forecast

Average 8.64 USD  71.09%

High 18 USD

Low 4 USD

Based on 14 Wall Street analysts offering 12 month price targets forMyriad Genetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

4

Buy

8

Hold

2

Sell

Technical Score

By Trading Central

N/A / 7.55Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

165 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.